Market News Call

Watch List: Sequenom, Inc. (NASDAQ:SQNM), Gilead Sciences, Inc.(NASDAQ:GILD), Novavax, Inc. (NASDAQ:NVAX)

Lakeway, NY — (MARKET NEWS CALL) — 11/01/2013 —, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Sequenom, Inc. (NASDAQ:SQNM), Gilead Sciences, Inc.(NASDAQ:GILD), Novavax, Inc. (NASDAQ:NVAX).

Sequenom, Inc. (NASDAQ:SQNM) shares dropped 22.58% to $1.92. The Enzo Clinical Labs subsidiary of Enzo Biochem, Inc. (ENZ) on Oct. 29 has entered into an agreement to market in its northeast U.S. service area a proprietary early non-invasive prenatal laboratory test (“LDT”) service, MaterniT21 PLUS ™, developed by the Sequenom Laboratories, Inc., subsidiary of Sequenom, Inc. (SQNM).

Should Investors Buy SQNM After Yesterday’s Slump? Find Out Here

Additionally, the company announced it will report financial results for the third quarter of 2013 after closing of the NASDAQ Global Market on Thursday, November 7, 2013.

Gilead Sciences, Inc.(NASDAQ:GILD) shares decreased 2.06% to $71.18. The company on Oct. 30 posted strong third-quarter sales and raised its annual forecast. Gilead said sales of its HIV drugs including Atripla, Stribild, and Truvada grew 14 percent to $2.33 billion and its overall revenue totaled $2.78 billion. That was about $60 million more than analysts expected. Excluding special items the company said it earned 52 cents per share, 4 cents more than Wall Street had expected.

Can Traders Buy GILD After The Solid Rally? Get Free Trend Analysis Here

The company said it now expects between $10.3 billion and $10.4 billion in revenue this year, up from its previous guidance of $10 billion to $10.2 billion.

Novavax, Inc. (NASDAQ:NVAX) shares closed at $3.10. The company announced today that it will host a conference call and live webcast to report its third quarter 2013 financial results on Thursday, November 7, 2013, at 4:30 p.m. ET.

Should Investors Rush To Buy NVAX After The Solid Rally? Get Special Report Here

Aditionally, the company on Oct. 7 announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age. This randomized, blinded, placebo-controlled Phase 2 study will evaluate the immunogenicity and safety of multiple formulations of Novavax’ RSV-F protein nanoparticle vaccine candidate with aluminum phosphate as an adjuvant.

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Tags: , , , , ,

Leave your comment here